BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10353601)

  • 1. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
    Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
    Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
    Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
    Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
    Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
    Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
    J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
    Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
    Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
    Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
    J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
    Goldberg L; Israeli R; Kloog Y
    Cell Death Dis; 2012 Mar; 3(3):e284. PubMed ID: 22419113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras chaperones: new targets for cancer and immunotherapy.
    Kloog Y; Elad-Sfadia G; Haklai R; Mor A
    Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Ras antagonist blocks human melanoma growth.
    Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
    Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
    Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
    Santen RJ; Lynch AR; Neal LR; McPherson RA; Yue W
    Anticancer Drugs; 2006 Jan; 17(1):33-40. PubMed ID: 16317288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
    Oron T; Elad-Sfadia G; Haklai R; Aizman E; Brazowski E; Kloog Y; Reif S
    Dig Dis Sci; 2012 Feb; 57(2):320-6. PubMed ID: 21901261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
    Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
    Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
    Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
    Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
    Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
    Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.
    Halaschek-Wiener J; Wacheck V; Schlagbauer-Wadl H; Wolff K; Kloog Y; Jansen B
    Mol Med; 2000 Aug; 6(8):693-704. PubMed ID: 11055588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
    Aizman E; Mor A; Levy A; George J; Kloog Y
    Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.